FDA, EMA Come Down Hard on Oral KetoconazoleFDA, EMA Come Down Hard on Oral Ketoconazole

The EMA recommends pulling the antifungal tablets from the markets; the FDA says clinicians should drop them as a first-line therapy because of the risk for severe liver injury and other problems. News Alerts
Source: Medscape Infectious Diseases Headlines - Category: Infectious Diseases Tags: Infectious Diseases News Alert Source Type: news